Immunotherapy in the initial treatment of newly diagnosed cancer patients: Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer

Ya Chen Tina Shih, Linda S. Elting, Alexandre L. Pavluck, Andrew Stewart, Michael T. Halpern

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

We analyzed the utilization trend for immunotherapy as initial treatment in the United States and estimated the cost impact of three cancers for which the majority of newly approved immunotherapies were indicated: non-Hodgkin's lymphoma (NHL), metastatic breast cancer (MBC), and metastatic colorectal cancer (MCRC). Utilization was highly concentrated, with four cancers accounting for 7080 of use. On the basis of the pattern in 2004 (22.9 NHL, 3.2 MCRC, and 3.3 MBC), immunotherapy was associated with $285, $73, and $12 million cost increase for NHL, MCRC, and MBC, respectively. Costs for these cancers would have exceeded $1.82 billion had 50 of eligible patients received immunotherapy.

Original languageEnglish (US)
Pages (from-to)46-53
Number of pages8
JournalCancer Investigation
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2010

Keywords

  • Health sciences research
  • Monoclonal antibodies
  • Outcomes research

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunotherapy in the initial treatment of newly diagnosed cancer patients: Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this